{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:04:23Z","timestamp":1793289863926,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacc.2024.07.035","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:04:28Z","timestamp":1728468268000},"page":"2026-2036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Recaticimab Monotherapy for Nonfamilial\u00a0Hypercholesterolemia and\u00a0Mixed Hyperlipemia"],"prefix":"10.1016","volume":"84","author":[{"given":"Mingtong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengsheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xitian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfa","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-9528","authenticated-orcid":false,"given":"Zhiyu","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-7332","authenticated-orcid":false,"given":"JunBo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.07.035_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib2","first-page":"1","article-title":"2016 Chinese guidelines for the management of dyslipidemia in adults","volume":"15","year":"2018","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib3","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.07.035_bib5","first-page":"237","article-title":"Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management (2023)","volume":"38","year":"2023","journal-title":"Chin Circ J"},{"key":"10.1016\/j.jacc.2024.07.035_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.07.035_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation Cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacc.2024.07.035_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.12.069","article-title":"Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults","volume":"260","author":"Zhang","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib9","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacc.2024.07.035_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.07.035_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijcard.2008.11.033","article-title":"Trends in hypercholesterolemia, treatment and control among United States adults","volume":"140","author":"Ford","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of statin intolerance in 2018: still more questions than answers","volume":"18","author":"Toth","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2024.07.035_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2016.07.009","article-title":"Statin intolerance: a literature review and management strategies","volume":"59","author":"Saxon","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2024.07.035_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"Group","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.07.035_bib15","first-page":"221","article-title":"Joint Committee on the Chinese Guidelines for Lipid Management. [Chinese guidelines for lipid management (2023)]","volume":"51","year":"2023","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.jacc.2024.07.035_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/aps.2016.134","article-title":"Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives","volume":"38","author":"He","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jacc.2024.07.035_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.07.035_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.07.035_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","article-title":"PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study","volume":"20","author":"Xu","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2024.07.035_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/jns5.12048","article-title":"Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies","volume":"18","author":"Berger","year":"2013","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.jacc.2024.07.035_bib22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","article-title":"Efficacy and safety of long-term evolocumab use among Asian subjects- a subgroup analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial","volume":"85","author":"Keech","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2024.07.035_bib23","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.07.035_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.035_bib25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.07.035_bib26","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","article-title":"Alirocumab after acute coronary syndrome in patients with a history of heart failure","volume":"43","author":"White","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724080379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724080379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T03:48:07Z","timestamp":1763092087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724080379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0735109724080379"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.07.035","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recaticimab Monotherapy for Nonfamilial\u00a0Hypercholesterolemia and\u00a0Mixed Hyperlipemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}